查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1837124

移植诊断市场（按诊断应用、技术、器官类型和最终用户划分）—2025-2032 年全球预测

Transplant Diagnostics Market by Diagnostic Application, Technology, Organ Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，移植诊断市场规模将成长至 90.1 亿美元，复合年增长率为 7.88%。

主要市场统计数据
基准年2024年 49.1亿美元
预计2025年 52.9亿美元
预测年份：2032年 90.1亿美元
复合年增长率（%） 7.88%

全面介绍移植诊断，描述分子创新、临床工作流程和指导护理途径的监管要求的融合

移植诊断处于免疫学、分子生物学和临床工作流程优化的关键交叉点，快速可靠的诊断是患者预后和计画永续性的基础。分子检测、次世代定序和数位PCR的最新进展扩展了临床医生和实验室主任可用的诊断套件，从而能够更准确地进行供体-受体匹配、更早地发现移植物损伤以及进行更精细的病原体监测。这些技术进步与营运趋势相辅相成，这些趋势强调更快的周转速度、自动化数据整合以及可扩展的实验室模型，这些模型可以在不牺牲分析严谨性的情况下支援高通量检测。

因此，从移植中心到诊断实验室的相关人员正在重新调整临床路径和采购流程，以在控製成本和复杂性的同时，充分挖掘先进诊断技术的临床价值。同时，监管机构对检测验证、资料完整性和互通性的关注度日益提高，这推动了对标准化工作流程和证据产生的需求。因此，领导者必须权衡新型检测方法的临床效益与营运现实，并协调临床、实验室和行政部门的相关人员，确保诊断创新转化为移植器官存活率和病人安全的可衡量改善。

新的分子平台、数位整合和协作证据产生如何重塑移植诊断的临床实践和采用途径

随着新技术、以数据为中心的护理模式以及不断发展的临床方案的融合，移植诊断的模式正在发生变化，从而重新定义标准实践。首先，分子诊断正在从单一分析物检测转向多重和基于序列的方法，从而提供更丰富的免疫遗传学和病原体谱。这种转变正在改变移植团队处理捐赠者选择、免疫抑制管理和移植后监测的方式，因为临床医生现在可以获得纵向的生物标记轨迹，而不是孤立的简介。

其次，实验室自动化和数位化整合正在减少人工差异，缩短检测週转时间。因此，移植计画正在采用更积极的监测方案，以便更早发现移植物损伤，并及时调整治疗方案。第三，监管和报销格局正在不断发展，以解决新型诊断方法的临床效用和证据阈值，促使製造商和医疗系统投资于真实世界证据研究和支付方参与。最后，诊断公司、临床中心和数据平台之间的伙伴关係正在加速伴随诊断和标准化报告框架的开发，这些合作降低了应用门槛，并为在不同医疗环境中的可扩展部署开闢了道路。

评估近期美国关税对移植诊断采购、製造和临床工作流程的营运和供应链影响

2025年，美国实施的关税政策为依赖全球供应链的製造商、实验室和临床计画带来了额外的复杂性。依赖进口的组件，例如专用试剂、仪器零件和定序耗材，正面临采购成本增加和采购计画中断的问题。这直接导致实验室管理人员必须重新评估其供应商关係，多元化供应商网络，在某些情况下，还要优先考虑安全库存，以保持检测服务的连续性。

同时，製造商正在透过合理化其区域製造地和加快本地化进程来应对，以减少与关税相关的波动带来的影响。此类调整通常需要大量的资本投入和较长的前置作业时间才能实现成本效益。同时，在固定报销制度下运作的临床项目正面临营业利润率的压力、更严格的检测利用优先顺序以及更严格的成本效益审查。为此，许多相关人员正在采用策略筹资策略，优化批次处理，并重组工作流程以整合临床适用的检测。从中期来看，供应链弹性、供应商多元化和合约灵活性可能会成为寻求维持服务连续性和管理贸易政策变化财务影响的组织必不可少的能力。

深入的細項分析揭示了诊断应用、技术模式、器官特定需求和最终用户结构如何影响采用和投资重点

详细了解细分市场可以提供切实可行的见解，了解临床需求和技术采用之间的分歧所在。从诊断应用的角度来看，供体-受体匹配、移植物监测、 HLA型检测和传染病筛检各自占据不同的临床路径，具有不同的分析优先顺序。 HLAHLA型检测代表双重解析度需求：高解析度检测能够对复杂病例进行准确的等位基因水平匹配，而低解析度方法仍能满足常规相容性筛检。传染病筛检涵盖细菌、真菌和病毒领域，病毒监测本身需要针对巨细胞病毒、EB病毒、肝炎病毒和 HIV 等病原体进行有针对性的检测，每种病毒都对实验室施加了特定的灵敏度和周转限制。

酵素测定和流式细胞技术在许多诊断工作流程中起着基础性的作用，而 PCR 方法（包括定量 PCR 和数位 PCR）则可提供高度灵敏的定量分析，可用于病毒量监测和微小残留疾病检测。新一代定序和桑格定序技术越来越多地应用于表征 HLA 等位基因和对复杂病原体基因型鉴定，从而产生支持个性化免疫抑制策略的高解析度数据。器官类型细分揭示了心臟、肾臟、肝臟、肺部和胰臟移植的不同临床需求，揭示了因移植物特异性生物标记、监测频率和风险接受度而异的检测模式。最后，最终用户细分揭示了诊断实验室、医院、研究机构和移植中心的运作观点。在医院内部，私立和公立机构之间的差异会影响采购模式、预算限制和实施时间表。结合这些相交的部分，可以揭示在检测开发、实验室自动化和临床检验方面的投资在哪些方面可以产生最大的临床和营运影响。

区域资讯详细说明了临床能力、监管多样性和供应链动态如何推动全球医疗保健市场的差异化采用模式

区域动态对于理解临床实践、法律规范和报销政策如何影响移植护理中的诊断采用至关重要。在美洲，临床网路和集中实验室通常优先考虑快速分子检测和精简的供应管道，主要移植中心成为影响国家实践的早期采用者和参考中心。在欧洲、中东和非洲，法规环境、报销系统和实验室基础设施的多样性导致了不同的采用率，一些先进的实践与资源受限的环境共存，后者优先考虑具有成本效益的稳健测试。在亚太地区，实验室能力的快速投资，加上临床数量的增加和对国内製造业的重视，加速了定序和基于 PCR 的诊断方法的采用，特别是在都市区三级医疗中心。

在这些全部区域，互通性、统一的标准和跨境资料共用对于多中心合作研究和纵向监测计画仍然至关重要。因此，区域策略必须将全球最佳实践与当地监管现状和供应链考量相协调，并实现可扩展的实施，同时尊重临床工作流程和付款人系统的差异。策略性区域伙伴关係和以本地为重点的检验研究是弥合能力差距并将创新诊断方法引入不同医疗生态系统常规实践的有效机制。

竞争格局分析强调了专业创新者、平台提供者和资讯解决方案之间的相互作用，这将决定市场领导地位和临床应用

移植诊断领域的竞争态势反映了专业创新企业与大型平台供应商之间的平衡，后者提供涵盖检测、设备和资讯学的一体化解决方案。利基市场公司通常引领检测创新，提供高解析度HLA型检测、标靶病毒监测面板以及针对特定未满足临床需求的新型生物标记方法。相较之下，大型公司则利用其规模优势投资实验室自动化、全球分销网路和监管项目，以推动更广泛的市场渗透。检测开发商、设备製造商和临床网路之间的伙伴关係和策略联盟日益普遍，这为检验临床效用并透过现有管道加速应用提供了途径。

同时，能够实现标准化彙报、纵向资料视觉化以及与电子健康记录整合的软体和资讯学公司正成为关键的竞争优势。这些功能透过将原始检测结果转化为移植临床医生可操作的见解，从而增强了临床效用。随着竞争加剧，围绕专有检测方法的知识产权、与现有检测生态系统整合的便捷性以及展示真实世界临床结果的能力将决定哪些公司能够成功获得移植中心和参考实验室的青睐。

为诊断开发人员、实验室和临床领导者提供可行的建议，以使证据产生、互通性和弹性供应策略与采用目标保持一致

行业领导者必须优先考虑证据生成、互通性和供应链弹性，以将技术前景转化为常规临床实践。首先，新诊断产品的申办者必须投资于严格的临床检验研究和真实世界证据项目，以证明其在代表性移植族群和医疗环境中的临床效用。这种方法将增强临床医生的信心和付款人的参与度，同时提供适当的使用指南。其次，供应商和实验室必须透过采用标准化报告格式、电子健康记录API和实验室资讯系统整合来设计互通性。

第三，建立灵活的供应链，涵盖多家合格供应商、区域性生产应急计画以及库存管理策略，可以降低外部政策和物流中断带来的营运风险。第四，商业策略应强调与医院和付款人进行基于价值观的对话，并根据临床结果、工作流程效率和总护理成本来製定诊断方案。最后，与移植中心和研究机构进行合作试点，为实证应用开闢道路，并提供可操作的回馈循环，以改善产品设计和服务模式。

一种透明而严谨的调查方法，结合临床文献、监管指导和该领域从业人员的见解来支持基于证据的结论

本执行摘要所依据的研究整合了同行评审文献、监管指南、官方临床指南和最新的行业揭露，以确保观点的平衡性和实证性。一级资讯来源包括临床检验研究、检测性能报告以及说明检测方法和分析特性的技术白皮书。我们审查了监管文件和指导声明，以了解对验证、报告和实验室品质保证不断变化的期望。此外，实验室主任、移植临床医生和供应链经理的定性意见为实施、週转和采购提供了切实可行的考虑。

为确保分析的严谨性，我们将技术论点与独立评估进行交叉引用，并优先考虑多中心研究和成熟临床计画的数据。在讨论实务意义时，我们运用个案和实务经验来阐明常见的障碍和缓解措施。本报告着重调查方法透明度，附录详细说明了纳入标准、来源层级和研究局限性，以支持同侪复製和严格评估。

总结性结论强调了技术成熟度、营运弹性和协作证据产生将如何决定移植诊断的临床影响和采用轨迹

先进分子技术、实验室自动化以及日益增长的临床期望的整合，使移植诊断成为改善移植结果和患者安全的关键工具。从供体选择和HLA型检测到感染疾病监测和移植物监测，高解析度检测方法和整合资料工作流程在临床路径中的应用正在重塑医疗决策。同时，贸易政策变化和区域能力差距等外部压力凸显了对弹性供应链、本地化检验和灵活实施策略的需求。

展望未来，那些将严谨的证据生成、可互通的系统设计和策略性商业性合作相结合的相关人员，将最有能力将诊断创新转化为可衡量的临床价值。检测开发人员、临床中心和资讯学提供者之间的跨部门合作将加速这一转变，使诊断从一次性检测转变为持续的、数据驱动的监测，从而主动管理患者并改善长期疗效。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 结合液态生物检体与游离DNA检测来检测早期器官排斥
  • 引入人工智慧驱动的影像分析，用于移植诊断中的准确组织病理学评估
  • 引入多重免疫检测，同时监测供体特异性抗体和免疫标记
  • 扩展照护现场检测平台，实现移植相关感染疾病的快速检测
  • 开发非侵入性尿液生物标记组以预测功能衰退前的慢性移植物功能障碍
  • 影响移植基因表现表现谱检测市场进入的监管核准和报销挑战

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 移植诊断市场（依诊断应用）

  • 捐赠者和接受者匹配
  • 移植物监测
  • HLA型检测
    • 高解析度
    • 低解析度
  • 传染病筛检
    • 细菌筛检
    • 真菌检测
    • 病毒筛检
      • 巨细胞病毒
      • EB病毒
      • 肝炎病毒
      • HIV

9. 移植诊断市场（依技术）

  • 酵素测定
  • 流式细胞技术
  • PCR
    • 数位PCR
    • QPCR
  • 定序
    • 新一代
    • 桑格定序

第 10 章。按器官类型分類的移植诊断市场

  • 心
  • 肾
  • 肝
  • 肺
  • 胰臟

第 11 章 移植诊断市场（依最终使用者）

  • 诊断实验室
  • 医院
    • 私立医院
    • 公立医院
  • 研究所
  • 移植中心

第十二章 移植诊断市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 移植诊断市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国移植诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • F. Hoffmann-La Roche Ltd
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • Danaher Corporation
    • Illumina, Inc.
    • Qiagen NV
    • Bio-Rad Laboratories, Inc.
    • DiaSorin SpA
    • CareDx, Inc.
    • Natera, Inc.
Product Code: MRR-031685195790

The Transplant Diagnostics Market is projected to grow by USD 9.01 billion at a CAGR of 7.88% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.91 billion
Estimated Year [2025] USD 5.29 billion
Forecast Year [2032] USD 9.01 billion
CAGR (%) 7.88%

A comprehensive introduction to transplant diagnostics that explains the convergence of molecular innovation, clinical workflows, and regulatory imperatives guiding care pathways

Transplant diagnostics occupies a pivotal intersection of immunology, molecular biology, and clinical workflow optimization, where rapid and reliable diagnostics underpin patient outcomes and program sustainability. Recent advances in molecular assays, next-generation sequencing, and digital PCR have expanded the diagnostic toolkit available to clinicians and laboratory directors, enabling more precise donor-recipient matching, earlier detection of graft injury, and refined pathogen surveillance. These technological improvements are complemented by operational trends that emphasize faster turnaround, automated data integration, and scalable laboratory models that can support high-throughput testing without sacrificing analytical rigor.

Consequently, stakeholders from transplant centers to diagnostic laboratories are recalibrating clinical pathways and procurement processes to capture the clinical value of advanced diagnostics while managing cost and complexity. In parallel, regulatory attention on assay validation, data integrity, and interoperability is intensifying, which drives a greater need for standardized workflows and evidence generation. As a result, leaders must weigh the clinical benefits of novel assays against implementation realities, aligning stakeholders across clinical, laboratory, and administrative functions to ensure that diagnostic innovations translate into measurable improvements in graft survival and patient safety.

How emerging molecular platforms, digital integration, and collaborative evidence generation are reshaping clinical practice and adoption pathways in transplant diagnostics

The landscape of transplant diagnostics is shifting as emerging technologies, data-centric care models, and evolving clinical protocols converge to redefine standard practice. First, molecular diagnostics are moving from single-analyte tests toward multiplexed and sequencing-based approaches that deliver richer immunogenetic and pathogen profiles. This transition is changing how transplant teams approach donor selection, immunosuppression management, and post-transplant surveillance, because clinicians now have access to longitudinal biomarker trajectories rather than isolated snapshots.

Second, laboratory automation and digital integration are reducing manual variability and shortening test turnaround times, which supports more dynamic clinical decision-making. As a result, transplant programs are able to adopt more proactive monitoring regimens that detect graft injury earlier and enable timely therapeutic adjustments. Third, the regulatory and reimbursement environment is evolving to address clinical utility and evidence thresholds for novel diagnostics, prompting manufacturers and health systems to invest in real-world evidence studies and payer engagement. Finally, partnerships between diagnostics firms, clinical centers, and data platforms are accelerating the development of companion diagnostics and standardized reporting frameworks, which together lower barriers to adoption and create pathways for scalable implementation across diverse healthcare settings.

Evaluating the operational and supply chain repercussions of recent United States tariff measures on transplant diagnostics procurement, manufacturing, and clinical workflows

In 2025, tariff policies introduced in the United States have introduced an additional layer of complexity for manufacturers, laboratories, and clinical programs that rely on global supply chains. Import-dependent components, including specialized reagents, instrumentation parts, and sequencing consumables, face increased procurement costs and disrupted sourcing timelines. As an immediate consequence, laboratory managers have had to reassess vendor relationships, diversify supplier networks, and in some cases prioritize inventory safety stock to preserve continuity of testing services.

At the same time, manufacturers are responding by rationalizing regional manufacturing footprints and accelerating localization efforts to mitigate exposure to tariff-related volatility. These adjustments often require substantial capital investment and longer lead times to realize cost benefits. Meanwhile, clinical programs that operate under fixed reimbursement regimes feel pressure on operating margins, prompting tighter prioritization of test utilization and greater scrutiny over cost-effectiveness. In response, many stakeholders are adopting strategic sourcing strategies and reengineering workflows to optimize batch processing and consolidate testing where clinically appropriate. Over the medium term, supply chain resilience, supplier diversification, and contractual flexibility will become essential capabilities for organizations seeking to maintain service continuity and manage the financial impacts of trade policy shifts.

Insightful segmentation analysis revealing how diagnostic application, technological modality, organ-specific needs, and end-user structures shape adoption and investment priorities

A granular understanding of market segments provides actionable insight into where clinical demand and technology adoption are diverging. When viewed through diagnostic application lenses, donor and recipient matching, graft monitoring, HLA typing, and infectious disease screening occupy distinct clinical pathways with different analytical priorities. HLA typing presents a duality of resolution needs where high-resolution assays enable precise allele-level matching for complex cases while low-resolution approaches continue to satisfy routine compatibility screening. Infectious disease screening spans bacterial, fungal, and viral domains, with viral surveillance itself requiring targeted assays for pathogens such as cytomegalovirus, Epstein-Barr virus, hepatitis viruses, and HIV, each of which imposes specific sensitivity and turnaround constraints on laboratories.

Technology segmentation further clarifies adoption trajectories: enzymatic assays and flow cytometry maintain foundational roles in many diagnostic workflows, while PCR modalities, including quantitative PCR and digital PCR, deliver high-sensitivity quantitation useful for viral load monitoring and minimal residual disease detection. Sequencing technologies, both next-generation and Sanger, are increasingly applied for HLA allele characterization and complex pathogen genotyping, yielding higher-resolution data that supports personalized immunosuppression strategies. Organ-type segmentation highlights differentiated clinical requirements across heart, kidney, liver, lung, and pancreas transplantation, where graft-specific biomarkers, monitoring frequency, and risk tolerances drive distinct testing patterns. Finally, end-user segmentation reveals the operational perspectives of diagnostic laboratories, hospitals, research institutes, and transplant centers; within hospitals, the distinction between private and public institutions affects procurement models, budgetary constraints, and adoption timelines. Together, these intersecting segmentations elucidate where investments in assay development, laboratory automation, and clinical validation will produce the greatest clinical and operational impact.

Regional intelligence detailing how clinical capacity, regulatory diversity, and supply chain dynamics drive differentiated adoption patterns across global healthcare markets

Regional dynamics are critical to understanding how clinical practice, regulatory frameworks, and reimbursement policies influence diagnostic adoption in transplant care. In the Americas, clinical networks and centralized laboratories often prioritize rapid molecular assays and streamlined supply channels, with major transplant centers serving as early adopters and reference hubs that influence national practices. In Europe, Middle East & Africa, heterogeneity in regulatory environments, reimbursement mechanisms, and laboratory infrastructure produces a wide spectrum of adoption rates, where pockets of advanced practice coexist with resource-constrained settings that emphasize cost-effective, robust assays. In the Asia-Pacific region, rapid investments in laboratory capacity, combined with growing clinical volumes and a focus on domestic manufacturing, are driving accelerated uptake of sequencing and PCR-based diagnostics, especially in urban tertiary centers.

Across these regions, interoperability, harmonized standards, and cross-border data sharing remain pivotal for multicenter studies and longitudinal surveillance programs. Consequently, regional strategies must reconcile global best practices with local regulatory realities and supply chain considerations, enabling scalable implementations that respect differences in clinical workflows and payer systems. Strategic regional partnerships and localized validation studies are effective mechanisms to bridge capability gaps and to translate innovative diagnostics into routine practice across diverse healthcare ecosystems.

Competitive landscape analysis emphasizing the interplay of specialized innovators, platform providers, and informatics solutions that determine market leadership and clinical adoption

Competitive dynamics in transplant diagnostics reflect a balance between specialized innovators and larger platform providers that offer integrated solutions spanning assays, instrumentation, and informatics. Niche firms often lead in assay innovation, delivering high-resolution HLA typing, targeted viral surveillance panels, and novel biomarker approaches that address specific unmet clinical needs. Larger entities, by contrast, leverage scale to invest in laboratory automation, global distribution networks, and regulatory programs that facilitate broader market penetration. Partnerships and strategic alliances between assay developers, instrument manufacturers, and clinical networks are increasingly common, providing a pathway to validate clinical utility and to accelerate adoption through established channels.

In parallel, software and informatics players are becoming critical competitive differentiators by enabling standardized reporting, longitudinal data visualization, and integration with electronic health records. These capabilities enhance clinical utility by converting raw assay outputs into actionable insights for transplant clinicians. As competition intensifies, intellectual property around proprietary assays, ease of integration with existing laboratory ecosystems, and the ability to demonstrate real-world clinical outcomes will determine which companies successfully capture preference among transplant centers and reference laboratories.

Actionable recommendations for diagnostics developers, laboratories, and clinical leaders to align evidence generation, interoperability, and resilient supply strategies with adoption goals

Industry leaders should prioritize evidence-generation, interoperability, and supply chain resilience to convert technological promise into routine clinical practice. First, sponsors of new diagnostics must invest in rigorous clinical validation studies and real-world evidence programs that demonstrate clinical utility across representative transplant populations and care settings. This approach accelerates clinician trust and payer engagement, while informing appropriate use guidelines. Second, vendors and laboratories should design for interoperability by adopting standardized reporting formats, APIs for electronic health records, and laboratory information system integrations that reduce implementation friction and enable scalable deployment across hospital networks.

Third, building flexible supply chains with multiple qualified suppliers, regional manufacturing contingencies, and inventory management strategies will mitigate the operational risk of external policy and logistics disruptions. Fourth, commercial strategies should emphasize value-based conversations with hospitals and payers, framing diagnostics in terms of clinical outcomes, workflow efficiency, and total cost of care. Finally, fostering collaborative pilots with transplant centers and research institutes creates an evidence-driven pathway for adoption and provides practical feedback loops that refine product design and service models.

A transparent and rigorous research methodology combining clinical literature, regulatory guidance, and frontline practitioner insights to support evidence-based conclusions

The research underpinning this executive summary synthesized peer-reviewed literature, regulatory guidance, public clinical guidelines, and recent industry disclosures to ensure a balanced, evidence-based perspective. Primary sources included clinical validation studies, assay performance reports, and technical white papers that describe assay methodologies and analytical characteristics. Regulatory documents and guidance statements were reviewed to capture evolving expectations for validation, reporting, and laboratory quality assurance. In addition, qualitative inputs from laboratory directors, transplant clinicians, and supply chain managers informed practical considerations around implementation, turnaround, and procurement.

Analytical rigor was maintained through cross-referencing technical claims against independent evaluations and by prioritizing data from multicenter studies and established clinical programs. Where real-world operational impacts were discussed, case examples and implementation lessons were used to illustrate common barriers and mitigation strategies. Methodological transparency is central to the report, and appendices detail inclusion criteria, source hierarchies, and limitations to support reproducibility and critical appraisal by technical audiences.

Concluding synthesis highlighting how technological maturation, operational resilience, and collaborative evidence generation will determine the clinical impact and adoption trajectory of transplant diagnostics

The convergence of advanced molecular technologies, enhanced laboratory automation, and heightened clinical expectations positions transplant diagnostics as a critical enabler of improved graft outcomes and patient safety. Throughout clinical pathways, from donor selection and HLA typing to infectious disease surveillance and graft monitoring, the adoption of higher-resolution assays and integrated data workflows is reshaping care decisions. At the same time, external pressures such as trade policy shifts and heterogeneous regional capabilities underscore the need for resilient supply chains, localized validation, and adaptable implementation strategies.

Moving forward, stakeholders who combine rigorous evidence generation, interoperable systems design, and strategic commercial engagement will be best positioned to translate diagnostic innovation into measurable clinical value. Cross-sector collaboration between assay developers, clinical centers, and informatics providers will accelerate this transition, enabling diagnostics to move from episodic testing toward continuous, data-driven monitoring that supports proactive patient management and improved long-term outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of liquid biopsy using cell-free DNA assays for early organ rejection detection
  • 5.2. Adoption of AI-driven image analysis for precise histopathological evaluation in transplant diagnostics
  • 5.3. Implementation of multiplex immunoassays for simultaneous monitoring of donor-specific antibodies and immune markers
  • 5.4. Expansion of point-of-care molecular testing platforms to enable rapid detection of transplant-related infections
  • 5.5. Development of noninvasive urinary biomarker panels to predict chronic allograft injury before functional decline
  • 5.6. Regulatory approval and reimbursement challenges influencing market access for gene expression profiling tests in transplantation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transplant Diagnostics Market, by Diagnostic Application

  • 8.1. Donor Recipient Matching
  • 8.2. Graft Monitoring
  • 8.3. Hla Typing
    • 8.3.1. High Resolution
    • 8.3.2. Low Resolution
  • 8.4. Infectious Disease Screening
    • 8.4.1. Bacterial Screening
    • 8.4.2. Fungal Screening
    • 8.4.3. Viral Screening
      • 8.4.3.1. Cytomegalovirus
      • 8.4.3.2. Epstein Barr Virus
      • 8.4.3.3. Hepatitis Viruses
      • 8.4.3.4. Hiv

9. Transplant Diagnostics Market, by Technology

  • 9.1. Enzymatic Assays
  • 9.2. Flow Cytometry
  • 9.3. Pcr
    • 9.3.1. Digital Pcr
    • 9.3.2. Qpcr
  • 9.4. Sequencing
    • 9.4.1. Next Generation
    • 9.4.2. Sanger

10. Transplant Diagnostics Market, by Organ Type

  • 10.1. Heart
  • 10.2. Kidney
  • 10.3. Liver
  • 10.4. Lung
  • 10.5. Pancreas

11. Transplant Diagnostics Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Research Institutes
  • 11.4. Transplant Centers

12. Transplant Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Transplant Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Transplant Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. F. Hoffmann-La Roche Ltd
    • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.3. Abbott Laboratories
    • 15.3.4. Danaher Corporation
    • 15.3.5. Illumina, Inc.
    • 15.3.6. Qiagen N.V.
    • 15.3.7. Bio-Rad Laboratories, Inc.
    • 15.3.8. DiaSorin S.p.A.
    • 15.3.9. CareDx, Inc.
    • 15.3.10. Natera, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. TRANSPLANT DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. TRANSPLANT DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TRANSPLANT DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GRAFT MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GRAFT MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GRAFT MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GRAFT MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GRAFT MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GRAFT MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIGH RESOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIGH RESOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIGH RESOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIGH RESOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIGH RESOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIGH RESOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LOW RESOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LOW RESOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LOW RESOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LOW RESOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LOW RESOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LOW RESOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY BACTERIAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY BACTERIAL SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY BACTERIAL SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY BACTERIAL SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY BACTERIAL SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY BACTERIAL SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FUNGAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FUNGAL SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FUNGAL SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FUNGAL SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FUNGAL SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FUNGAL SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EPSTEIN BARR VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EPSTEIN BARR VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EPSTEIN BARR VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EPSTEIN BARR VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EPSTEIN BARR VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EPSTEIN BARR VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ENZYMATIC ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ENZYMATIC ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ENZYMATIC ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ENZYMATIC ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ENZYMATIC ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ENZYMATIC ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY QPCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY QPCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY QPCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY QPCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY QPCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANGER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANGER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANGER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANGER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANGER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANGER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE,